VRTX
58
-2
OKE
71
-3
TDC
67
2
WHR
36
-10
KEY
50
11
MPC
52
10
HES
79
2
APD
32
3
PX
15
2
HOG
33
6
ROK
46
3
ADT
28
3
RIG
50
4
HCP
78
-2
PNR
72
10
EIX
54
-4
GIS
61
-2
VZ
30
3
PPG
64
3
DRI
48
-12
VRTX
58
-2
OKE
71
-3
TDC
67
2
WHR
36
-10
KEY
50
11
MPC
52
10
HES
79
2
APD
32
3
PX
15
2
HOG
33
6
ROK
46
3
ADT
28
3
RIG
50
4
HCP
78
-2
PNR
72
10
EIX
54
-4
GIS
61
-2
VZ
30
3
PPG
64
3
DRI
48
-12
Financhill
Back

NeuroMetrix 10K Form

Sell
46

NURO
NeuroMetrix

Last Price:
4.45
Seasonality Move:
13.67%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive NURO News And Ratings

See the #1 stock for the next 7 days that we like better than NURO

NURO Financial Statistics

Sales & Book Value

Annual Sales: $5.9M
Cash Flow: $-1.5M
Price / Cash Flow: 0
Annual Sales: $13.18
Price / Book: 0.44

Profitability

EPS (TTM): -5.88170
Net Income (TTM): $-6.53M
Gross Margin: $3.95M
Return on Equity: -30.58%
Return on Assets: -28.7%

NeuroMetrix Earnings Forecast

Key NeuroMetrix Financial Ratios

  • The Gross Profit Margin over the past 23 years for NURO is 66.89%.
  • The Selling, General & Administrative Expenses for NURO have been equal to 141.00% of Gross Profit Margin.
  • The Research & Development expenses have been 47.07% of Revenue.
  • The Interest Expense is 0.00% of Operating Income.
  • The Net Earning history of NURO is -110.64% of Total Revenues.
  • Per Share Earnings over the last 23 years have been positive in 13 years.

NeuroMetrix Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Health Care Equipment & Supplies
Sector: Health Care
Current Symbol: NURO
CUSIP: 641255
Website: neurometrix.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 16.81
Quick Ratio: 14.92

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

NURO Technical Analysis vs Fundamental Analysis

Sell
46
NeuroMetrix (NURO) is a Sell

Is NeuroMetrix a Buy or a Sell?

  • NeuroMetrix stock is rated a Sell
    The current NeuroMetrix [NURO] share price is $4.44. The Score for NURO is 46, which is 8% below its historic median score of 50, and infers higher risk than normal.